Misplaced Pages

Escitalopram

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by 164.116.47.179 (talk) at 16:30, 3 October 2005 (fixed chemical form). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 16:30, 3 October 2005 by 164.116.47.179 (talk) (fixed chemical form)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
escitalopram (free base) structure
escitalopram (free base) structure

escitalopram (free base)

IUPAC chemical name
CAS number
 ?
ATC code
 ?
Chemical formula C20H22FN2O+ C2HO4-
Molecular weight 414.40
Bioavailability ?
Metabolism ?
Elimination half-life ?
Excretion ?
Pregnancy category C
Legal status ?
Routes of administration ?

Escitalopram oxalate (also known as Lexapro and Cipralex) is a medication developed by the Danish pharmaceutical company Lundbeck, that acts as a selective serotonin reuptake inhibitor or SSRI. It is typically used as an antidepressant to treat depression associated with mood disorders although also may be used in the treatment of body dysmorphic disorder and anxiety.

Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designated S-(+)-1--1-( p -fluorophenyl)-5-phthalancarbonitrile oxalate with the molecular formula:

C20H22FN2O C2HO4

and the molecular weight is 414.40.

Escitalopram oxalate is derived from the drug citalopram which is made up of two mirror-image isomers, only one of which is thought to be an effective medication. Lundbeck has split the isomers apart, taken the active isomer and has licensed it as the new drug 'escitalopram'.

It is notable that escitalopram was released shortly before the patent for citalopram was due to expire. The expiration of a patent means other companies can legally produce cheaper generic versions. Escitalopram is subject to a new patent. Critics have argued that escitalopram, and the subsequent marketing campaign to persuade mental health professionals to prescribe it, is a cynical ploy to promote sales of a virtually identical but considerably more expensive drug. In defence of the new drug, Lundbeck have claimed that the drug has additional benefits over the older citalopram and other antidepressant drugs on the market.

In the United States, the drug is marketed under the name Lexapro by Forest Laboratories, Inc.

In Canada, the drug is marketed under the name Cipralex by Lundbeck Canada, Inc.

Externals links

Antidepressants (N06A)
Specific reuptake inhibitors and/or receptor modulators
SSRIsTooltip Selective serotonin reuptake inhibitors
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
Tricyclic and tetracyclic antidepressants
TCAsTooltip Tricyclic antidepressants
TeCAsTooltip Tetracyclic antidepressants
Others
Monoamine oxidase inhibitors
Non-selective
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Adjunctive therapies
Miscellaneous
Categories: